Labcorp Holdings Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adam H. Schechter
- Full Time Employees
- 71,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 358 South Main Street Burlington NC United States of America 27215
- IPO Date
- Mar 29, 1990
- CIK
- 0000920148
- Website
- labcorp.com
- Similar Companies
- Business
- Labcorp Holdings Inc. (NYSE: LH), headquartered in Burlington, North Carolina, and founded in 1971, operates as a global life sciences and healthcare company that provides comprehensive laboratory diagnostics and biopharma drug development services across more than 100 countries, with primary operations in the United States; the company conducts business through two main segments, Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics Laboratories segment offers routine clinical testing and specialty/esoteric testing, including over 5,000 tests in areas such as oncology, genetics and genomics, women's health, autoimmune diseases, neurology, HIV genotyping and phenotyping, employment screening, DNA parentage and immigration testing, environmental monitoring, wellness, toxicology, pain management, and medical drug monitoring, delivered via approximately 2,000 patient service centers, more than 6,000 in-office phlebotomists, rapid response laboratories, primary laboratories, specialty laboratories, and 50 at-home tests, processing over 700 million tests annually for patients, physicians, hospitals, health systems, managed care organizations, employers, governments, and consumers. The Biopharma Laboratory Services segment delivers end-to-end drug development, medical device, and diagnostic development support to pharmaceutical, biotechnology, medical device, crop protection, and chemical companies, encompassing early development research, central laboratory services, clinical trial testing, and companion diagnostics, supporting more than 75% of new FDA-approved drugs and therapeutics in 2024. In recent developments, Labcorp completed the acquisition of select oncology and clinical testing assets from BioReference Health in September 2025 for up to $225 million to bolster its oncology leadership; acquired assets of Invitae in August 2024 for $239 million to expand genetic testing capabilities; signed agreements to acquire select assets of Empire City Laboratories and Laboratory Alliance of Central New York in 2025 while progressing the Community Health Systems outreach business acquisition across 13 states; launched new Alzheimer's neurology tests, Labcorp Test Finder tool, and consumer tests via Labcorp OnDemand; invested $268.4 million in acquisitions and partnerships during Q3 2025; and expanded its credit facility to $700 million in January 2025.
Company News
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Should You Continue to Hold Labcorp Stock in Your Portfolio?
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp (NYSE:LH) Sets New 12-Month High – Time to Buy?
Labcorp to Host Investor Day on September 10, 2026
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
Labcorp Q2 Earnings Call Highlights
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript
LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise
Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Say
Labcorp Holdings (LH) Surpasses Q2 Earnings and Revenue Estimates
Labcorp raises annual profit forecast on strong testing demand
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance